Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (July 2026)
27 slides from Devonian Health's investor presentation, July 2026
Slide 1: THYKAMINE: An Innovative Therapeutic Platform for Inflammation and Fibrosis
TSXv – GSD l OTCQB – DVHGF THYKAMINE An Innovative Therapeutic Platform For Inflammation and Fibrosis July 2026 1
Slide 2: Disclaimer
Disclaimer This corporate presentation together with oral statements made in connection herewith (“Presentation”) has been prepared by DEVONIAN HEALTH GROUP INC. (“DEVONIAN” or the “Company”). This Presentation is subject to updating, completion, revision, verification and further amendment. This Pr
Slide 3: Devonian Health Group: Novel Plant-Derived Therapeutics
Devonian Health Group Novel Plant-Derived Therapeutics 1 1 Chen L., Deng H., Cui H., et al. Inflammatory responses and inflammation associated diseases in organs. Oncotarget, 9 (6):7204-7218, 2017 3
Slide 4: Executive Management Team
Built for Clinical Execution and Strategic Growth Proven Leadership with Biotech, Regulatory and Capital Markets Expertise Executive Management Team Leadership Background Dr. André P. Boulet, PhD Dennis Turpin, CPA Luc Grégoire, CPA President & CEO Chief Financial Officer Executive VP, Strategy Dr.
Slide 5: THYKAMINE Targets the Inflammation-Fibrosis Cascade
THYKAMINE Targets the Inflammation-Fibrosis Cascade1-6 Addressing upstream inflammatory pathways 1 Chen L., Deng H., Cui H., et al. Inflammatory responses and inflammation associated diseases in organs. Oncotarget, 9 (6):7204-7218, 2017 2 Hunter P. The inflammation theory of disease. EMBO, 13(11):96
Slide 6: THYKAMINE: An Innovative Therapeutic for Inflammation and Fibrosis
THYKAMINE : An Innovative Therapeutic for Inflammation and Fibrosis WHAT IS THYKAMINE ? Plant-derived supra-molecular therapeutic complex derived from thylakoid membrane structures. Combines anti-inflammatory and anti-fibrotic activity within a single therapeutic platform UNIQUE STRUCTURAL COMPOSITI
Slide 7: THYKAMINE Pipeline
THYKAMINE Pipeline Several clinical value inflection points EXPECTED MILESTONES DERMATOLOGY PRECLINICAL CANADIAN CTA (II III) / UNITED STATES IDE 12-18 MONTHS REG 510k ◆ Clinical Study Results Radiodermatitis EXPECTED MILESTONES DERMATOLOGY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 12-18 MONTHS Atopic der
Slide 8: Radiodermatitis: A Large, Unmet Prevention Opportunity
Radiodermatitis: A Large, Unmet Prevention Opportunity1,2 1 Zhu H, Kiang Chua ML, Chitapanarux I. et al. Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study. Lancet Glob Health;12: e1945–53; 2024 2 DIR
Slide 9: Radiodermatitis Treatment Landscape
Radiodermatitis Treatment Landscape 1 Lee, S.F., Shariati, S., Caini, S. et al. StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 31, 515, 2023. 2 Kuszaja O, Daya M, Wronskia M, et a
Slide 10: Radiodermatitis – THYKAMINE Study Design
Radiodermatitis – THYKAMINE Study Design1 10
Slide 11: THYKAMINE in Atopic Dermatitis (Eczema)
THYKAMINE in Atopic Dermatitis (Eczema) Phase II Study Results in Adult Mild-to-Moderate Atopic Dermatitis (AD)1 * * 11 1 Lynde et al. J Drugs Dermatol. 21( 10):1091-1097, 2022.
Slide 12: THYKAMINE Safety and Tolerability
THYKAMINE Safety and Tolerability Phase II Study in Adult Mild-to-Moderate Atopic Dermatitis1 GENERALLY WELL-TOLERATED – SIMILAR RATE OF ADVERSE EVENTS FOR PLACEBO AND THYKAMINE 12 1 Lynde et al. J Drugs Dermatol. 21( 10):1091-1097, 2022.
Slide 13: THYKAMINE Pediatric Atopic Dermatitis Phase II/III Clinical Study
THYKAMINE Pediatric Atopic Dermatitis Phase II/III Clinical Study1 13
Slide 14: THYKAMINE - Preclinical Results in MASH and Fibrosis
THYKAMINE - Preclinical Results in MASH and Fibrosis Robust anti-inflammation and fibrotic signal observed in multiple models 14
Slide 15: THYKAMINE Studies Harmonization
THYKAMINE STUDIES HARMONIZATION Designed and conducted as per International Council for Harmonisation (ICH) Global Standards Trials follow ICH guidelines — the internationally harmonised standard recognised by Health Canada, the U.S. FDA, and most regulatory agencies worldwide. 15
Slide 16: Vertically Integrated GMP Manufacturing Platform
THYKAMINE Vertically Integrated GMP Manufacturing Platform MANUFACTURING PLATFORM ✓ Proprietary 17,500 sq ft GMP extraction facility ✓ Integrated GMP manufacturing and CMC capabilities ✓ Scalable ANALYTICAL CONSISTENCY ✓ HPLC-MS and NMR fingerprint characterization ✓ Cell-based potency assay validat
Slide 17: Intellectual Property Portfolio
Intellectual Property Portfolio* 17
Slide 18: Cap Table & Summary Balance Sheet
Cap Table & Summary Balance Sheet ACTUAL1 AS OF CAP TABLE SUMMARY BALANCE SHEET 04/30/2026 Common Shares Outstanding 2,780,866 Cash USD$528,430 Warrants (WAEP: US$8.81)1 299,040 Total Assets USD$6,333,361 Options (WAEP: US$9.79)1 491,661 Total Liabilities USD$1,211,881 Fully Diluted Shares Outstandi
Slide 19: 18-Month Catalysts
18-Month Catalysts Multiple clinical, regulatory and platform-expansion milestones expected through 2027 2027 VALUE INFLECTION ROADMAP 19
Slide 20: Devonian Key Investment Highlights
Devonian First-in-class plant-derived multi-target anti-inflammatory platform THYKAMINE designed to modulate inflammatory and fibrotic pathways through Key Investment a differentiated supra-molecular mechanism. Positive Phase II Pediatric eczema safety data highlights Primary and secondary endpoints
Slide 21: Thank You – Questions?
THANK YOU Questions? DEVONIAN www.groupedevonian.com HEALTH GROUP
Slide 22: Appendix
Appendix 22
Slide 23: Superior Potency: THYKAMINE vs Commonly Used Corticosteroids
Superior Potency THYKAMINE vs Commonly Used Corticosteroids1 MIP-1 BETA (CCL4) • Potency assay • U937 human monocytic cell line • LPS stimulation induces inflammation and increase associated cytokines • THYKAMINE inhibits o MCP1 o MIP1α o MIP1β o RANTES • By dampening their production, THYKAMINE may
Slide 24: Lot Consistency - Chemical Composition
Lot Consistency - Chemical Composition1 ≥ 98% confidence Batches analyses HPLC-MS Batches analyses Nuclear Magnetic Resonnance (NMR) Confidence ≥ 98% 1 THYKAMINE Method Validation - Method Validation for Identification and Quantitation of Phytochemicals in Spinacia oleracea By High 24 Performance Li
Slide 25: Lot Consistency – Biological Function
Lot Consistency – Biological Function Potency Assay U-937 Human cell-based assay Inhibition of inflammatory response Dose-Response Curve Validation in progress* 25
Slide 26: Ulcerative Colitis: THYKAMINE Enema Phase IIa Clinical Results
Fibro-inflammation under Control Ulcerative Colitis THYKAMINE THYKAMINE Enema Phase IIa Clinical Results1 Impact on Mild-To-Moderate UC Symptoms and Markers Changes from Baseline as a Percentage (%) of the Mean Baseline Value and Strong Positive Trends Towards Superiority Over Placebo in Biomarker L
Slide 27: US $25B+ Global Market Opportunity
US $25B+ Global Market Opportunity1 1 Global Atopic Dermatitis Treatment Market – Forecast 2022 to 2027: Market Data Forecast, June 2022 27 27
Devonian Health Group — Investor Presentation (July 2026) on 6ix